PD-1 expression, 8 kinds of TILs and tumor mutational burden did not show better predictive power than MSC-score-based clustering for the evaluating PD-1 therapy response (Additional file 16: Fig. S7). The gene discussed is PDCD1; the disease is neoplasm.